Alnylam Pharmaceuticals (ALNY) Drops -17% in 30 Days: What's Behind the Slide
Key Takeaways
- ALNY shares declined roughly 17% over the last 30 days, falling from about $266 in early September to near $220 by early October.
- The drop extends a broader slide of about 30% over the last quarter and more than 44% year-to-date.
- Investor caution has centered on Amvuttra growth momentum, a cut to full-year revenue guidance, and reduced analyst price targets.
- Longer-term debates over the expanding RNAi pipeline and competitive dynamics in ATTR cardiomyopathy remain central to the stock's outlook.
A Closer Look at Alnylam Pharmaceuticals (ALNY) and Its Market Position
Alnylam Pharmaceuticals is a Cambridge, Massachusetts-based biopharmaceutical company widely regarded as the pioneer of RNA interference (RNAi) therapeutics. The company has translated the Nobel Prize-winning science of RNAi into six approved medicines, including Amvuttra and Onpattro for transthyretin amyloidosis (ATTR), Leqvio for hypercholesterolemia, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Qfitlia for hemophilia. Alnylam is executing its "Alnylam 2030" strategy, with a pipeline spanning cardiovascular, central nervous system, and rare disease indications, supported by collaborations with large pharmaceutical partners. Investors follow the stock closely for its commercial execution and clinical readouts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ALNY Stock Price Performance Over the Past 30 Days and Quarter
Over the last 30 days, ALNY declined about 17%, moving from a closing price near $266 in early September to roughly $220 by early October. The decline was uneven, with several sharp single-day moves, including a pronounced sell-off in the first two sessions of October. The stock closed at $219.72 on October 2, near the lower end of its 52-week range of $197.81 to $495.55, with its 50-day moving average near $241 and 200-day moving average near $303. From what I see, these technical levels help frame the current pressure on the shares.
Over the last quarter, the trend has been similarly negative. From a level around $313 in early July, shares have fallen roughly 30%, extending a decline of more than 44% year-to-date. This sustained downtrend reflects a combination of commercial execution concerns and shifting sentiment despite the company's established RNAi platform and broad pipeline.
Factors Behind the Recent 30-Day Decline in ALNY
The most recent leg lower was driven primarily by growing Wall Street caution. JPMorgan lowered its price target to $369 from $375, adjusting Amvuttra estimates to reflect prescription data, while maintaining an Overweight rating. Cantor Fitzgerald reiterated a Neutral rating, and Jefferies, though raising its target to $260 from $230, kept a Hold rating while flagging caution on tapering Amvuttra growth, uncertainty around the TRITON-CM program, and 340B dynamics.
Sentiment was further pressured by concerns that the strong initial Amvuttra launch in ATTR cardiomyopathy reflected pent-up demand that has since normalized, prompting Alnylam to cut its full-year revenue guidance. A four-year update on the company's Huntington's disease program also reminded investors how difficult it can be to demonstrate clear clinical benefit, reinforcing questions about near-term catalysts. I ran a quick check with Tickeron’s AI Pattern Search Engine and it aligned with the observed technical weakness.
Quarterly Performance Drivers and Competitive Landscape
The quarterly decline reflects a broader narrative shift. Alnylam reduced its full-year revenue guidance after early Amvuttra demand growth in ATTR-CM normalized, and analysts have weighed whether patient-start trends will reaccelerate. At the same time, the competitive landscape shifted in the company's favor: the Wainua program from AZN and IONS failed its primary endpoint in a late-stage ATTR cardiomyopathy trial, and PFE's Vyndamax franchise is insulated from generic competition until mid-2031. Despite the share decline, a majority of covering analysts maintained buy or strong buy ratings through late September, with consensus price targets implying substantial upside, underscoring the tension between long-term value and near-term execution risk.
What to Watch Next for ALNY Stock
Investors should monitor several catalysts ahead. Alnylam's next quarterly earnings report is expected around October 29, when management commentary on Amvuttra prescription trends and full-year guidance will be closely scrutinized. Additional data on the nucresiran Phase 3 program in ATTR-CM and ATTR-PN, as well as any further disclosures from rival programs, could influence sentiment. Hypertension readouts for zilebesiran and continued updates across the company's cardiovascular and central nervous system pipeline also matter. Macroeconomic conditions affecting biotech valuations, along with any changes in analyst ratings or price targets, will remain relevant to the stock's near-term direction.
Exploring AI Tools in My Research Process
When analyzing names like ALNY that move on both clinical and technical signals, I often turn to Tickeron’s automated platforms to cross-check patterns and sentiment. One resource I find useful is the Trending AI Robots page, which highlights bots with different strategies and timeframes that can complement fundamental work on volatile biotech stocks. Explore the Trending AI Robots page to see which strategies are currently gaining traction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
With a background in economics and swing trading, I write about market trends, technical setups, momentum, and opportunities that develop over several days or weeks. I combine economic perspective with practical trading experience to explain why stocks move, what trends may be developing, and which market signals are worth watching.
ALNY in upward trend: price may jump up because it broke its lower Bollinger Band on October 01, 2026
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 33 cases where ALNY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ALNY's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for ALNY crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
Following a +3.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 224 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 143 of 187 cases where ALNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In 56 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 32 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
ALNY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.253) is normal, around the industry mean (26.780). P/E Ratio (44.488) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics based on RNA interference
Industry Biotechnology
Advertisement